List of Immodulon Therapeutics Limited patents | 7 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11318193 Immunogenic treatment of cancer	Patent 11318193 was granted and assigned to Immodulon Therapeutics Limited on May, 2022 by the United States Patent and Trademark Office.	‌ Immodulon Therapeutics Limited	‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	11318193	May 3, 2022
‌ US Patent 11554166 Immunogenic treatment of cancer	Patent 11554166 was granted and assigned to Immodulon Therapeutics Limited on January, 2023 by the United States Patent and Trademark Office.	‌ Immodulon Therapeutics Limited	‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	11554166	January 17, 2023
‌ US Patent 10925952 Checkpoint inhibitor and a whole cell	Patent 10925952 was granted and assigned to Immodulon Therapeutics Limited on February, 2021 by the United States Patent and Trademark Office.	‌ Immodulon Therapeutics Limited	‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	10925952	February 23, 2021
‌ US Patent 10610577 Checkpoint inhibitor and a whole cell	Patent 10610577 was granted and assigned to Immodulon Therapeutics Limited on April, 2020 by the United States Patent and Trademark Office.	‌ Immodulon Therapeutics Limited	‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	10610577	April 7, 2020
‌ US Patent 10610578 Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy	Patent 10610578 was granted and assigned to Immodulon Therapeutics Limited on April, 2020 by the United States Patent and Trademark Office.	‌ Immodulon Therapeutics Limited	‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	10610578	April 7, 2020
‌ US Patent 8617520 Cancer therapy	Patent 8617520 was granted and assigned to Immodulon Therapeutics Limited on December, 2013 by the United States Patent and Trademark Office.		‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	8617520	December 31, 2013
‌ US Patent 10071124 Treatment of post-traumatic stress disorder with isolated	Patent 10071124 was granted and assigned to Immodulon Therapeutics Limited on September, 2018 by the United States Patent and Trademark Office.	‌ Immodulon Therapeutics Limited	‌ Immodulon Therapeutics Limited	United States Patent and Trademark Office	10071124	September 11, 2018